Invivyd, Inc. (NASDAQ:IVVD) Sees Large Increase in Short Interest

Invivyd, Inc. (NASDAQ:IVVD) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,980,000 shares, an increase of 8.4% from the December 31st total of 3,670,000 shares. Based on an average daily trading volume, of 958,500 shares, the short-interest ratio is currently 4.2 days. Approximately 5.3% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

IVVD has been the topic of a number of recent research reports. HC Wainwright reduced their target price on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Invivyd in a research note on Monday. Morgan Stanley lowered their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Invivyd has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Trading Up 196.3 %

IVVD stock opened at $1.06 on Tuesday. The firm has a market cap of $126.80 million, a P/E ratio of -0.54 and a beta of 0.61. The business’s 50 day moving average is $0.50 and its 200-day moving average is $0.82. Invivyd has a 1-year low of $0.35 and a 1-year high of $5.10.

Insider Activity

In other news, Director Terrance Mcguire sold 160,400 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00. Following the transaction, the director now directly owns 4,202,679 shares in the company, valued at $2,479,580.61. This represents a 3.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 816,466 shares of company stock valued at $423,214 over the last 90 days. Insiders own 17.90% of the company’s stock.

Hedge Funds Weigh In On Invivyd

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Proficio Capital Partners LLC bought a new position in shares of Invivyd in the 3rd quarter valued at about $27,000. Susquehanna Fundamental Investments LLC acquired a new position in Invivyd during the second quarter worth $115,000. Barclays PLC lifted its position in shares of Invivyd by 179.6% in the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after buying an additional 75,780 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after acquiring an additional 53,499 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of Invivyd in the second quarter valued at about $421,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.